Hybridan Research Comment Part 128 Apr 2025 21:11
Subject: Hybridan Research: Sareum Holdings plc: Assessing the Allocation of the Advancing Assets
Good afternoon,
Sareum Holdings PLC (SAR) gave a shareholder update on its various programmes today. We have published research on this which is attached and a snapshot of the research is below.
Progress is reported on Sareum’s most advanced assets which are the foundation of its near-term clinical strategy and development priorities. The October 2024 and March 2025 funding enables both simultaneous pipeline work, as well as new opportunities in the constantly evolving therapeutic landscape for kinase inhibitors.
Preclinical studies have been carried out to evaluate the potential of the TYK2/JAK1 inhibitors for autoimmune diseases in central nervous system indications (CNS). The study involved six compounds from Sareum's proprietary Sareum Kinase Inhibitor Library (SKIL) platform, tested in preclinical models to assess their ability to cross the Blood-Brain Barrier (BBB) which is a key requirement for CNS drug development. Three compounds demonstrated meaningful BBB penetration, with one showing strong levels of free drug in the brain. This work reflects growing scientific and commercial interest in the role of TYK2 inhibition in neuroinflammatory diseases such as Multiple Sclerosis, Parkinson's Disease, and Alzheimer's Disease which are areas with significant unmet medical need. The next step includes whether to progress one or more compounds into preclinical development.
In March 2025, Sareum secured full operational control of the licence for SRA737, which is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage. Sareum has now received the full clinical dataset for SRA737 including the Trial Master File and all associated documentation amounting to around 235Gb of data (incidentally this equals about 100 high-definition movies in equivalent Gb size). Sareum will be conducting a comprehensive review of the programme's potential considering the timing and cost of the strategic options available to it, which include re-licensing or advancing it in-house with or without a partner.
In 2024, SDC-1801 a dual TYK2/JAK1 inhibitor targeting autoimmune diseases successfully achieved a significant milestone by completing Phase 1 clinical trials in healthy volunteers. Comprehensive data from the Phase I study have been published on the Australian New Zealand Clinical Trials Registry. 16-week toxicology studies to support longer-term dosing in patients are expected to commence in May 2025, with completion anticipated in Q4, which gives further potential to substantially enhance SDC-1801’s value for licensing deals.
To be continued…
Sign In
Follow the stocks
